Innovative Cell Therapies Tessa Therapeutics specializes in next-generation autologous and allogeneic cell therapies targeting hematological cancers and solid tumors, positioning them as a leader in cutting-edge oncology treatments with high market potential.

Strong Clinical Pipeline With ongoing Phase 1b and Phase 2 clinical trials for therapies like TT11 and TT11X, Tessa offers opportunities for partnership and procurement of advanced cell therapy products once clinical success is demonstrated.

Recent Funding Success Having secured over 200 million dollars in recent financing rounds and investment from major venture capital firms, Tessa is well-funded to expand manufacturing capabilities and accelerate product development, creating avenues for strategic collaborations.

Recognition and Awards The company's accolades for its off-the-shelf therapies highlight its innovation edge and market credibility, making it a potential partner for distributors and healthcare providers seeking promising cell therapy solutions.

Strategic Location & Infrastructure Headquartered in Singapore with a state-of-the-art manufacturing facility, Tessa is ideally positioned to serve regional markets and collaborate with international pharmaceutical partners for global expansion.